Everything below concerns actin binding. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-07-13. Where a claim depends on a specific study, the study is described rather than over-claimed.
TB-500 refers to a synthetic peptide fragment derived from the actin-binding region of thymosin beta-4, a protein present in most mammalian cells. The full protein contains forty-three amino acids, while the commonly sold fragment is a much shorter acetylated sequence, often cited as LKKTETQ. The fragment retains part of the actin-binding motif but lacks the remainder of the parent protein. Material sold under this name is usually lyophilized powder intended for laboratory research, and it is not a finished pharmaceutical product.
Proposed activity centers on actin sequestration and on the movement of cells during repair processes. In cell culture and animal models, the fragment has been associated with migration, tube formation, and tissue remodeling. These observations are frequently described as preliminary, because most published work uses rodent or in vitro systems rather than controlled human trials. Whether the short fragment reproduces the effects of the full protein remains an open question, and the relationship between dose, route, and measured outcome is not well characterized.
The compound circulates in the literature as a research reagent rather than an approved therapeutic. Regulatory agencies in several countries have not authorized it for medical use, and sporting bodies list related thymosin beta-4 peptides among prohibited substances. Suppliers typically market it with a purity figure and a certificate of analysis, while peer-reviewed clinical reports remain sparse. Discussions therefore often separate laboratory findings from anecdotal reports, and reviewers tend to note the small size and methodological limits of the available studies.
TB-500 is a synthetic peptide preparation marketed under a name derived from thymosin beta-4, a 43-residue actin-binding protein first isolated from thymus tissue. The full-length protein has a reported molecular mass near 4963 Da, while material sold as TB-500 is often described as a fragment containing the actin-binding motif LKKTETQ. Because suppliers use the name inconsistently, published sources sometimes refer to the same label as a fragment, a synthetic copy, or a related analog. This naming ambiguity complicates direct comparison of reports across studies.
Laboratory work on thymosin beta-4 describes binding to monomeric actin and effects on cell migration, angiogenesis, and inflammatory signaling in cultured cells. Animal models have examined skin, corneal, and cardiac repair after injury, with outcomes reported mainly in preclinical literature. Most of that evidence concerns the parent protein rather than preparations labelled TB-500, so extrapolation from animal findings to a specific commercial product remains uncertain. Whether the two behave identically in living systems has not been established in controlled human studies.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized solid as supplied |
| Water solubility | Soluble | Dissolves in aqueous media |
| Typical storage temperature | -20 °C | Dry powder, desiccated, protected from light |
| Typical analytical method | RP-HPLC with mass spectrometry | Purity from peak area; mass for identity |
| Common synonyms | Tβ4 fragment; thymosin beta-4 fragment | Naming varies by supplier and catalogue |
Biological interest in this peptide centers on its relationship to actin dynamics. Thymosin beta-4 binds monomeric actin through an LKKTET motif, and a short sequence carrying that motif can compete with other actin-binding proteins in cell-free preparations. Investigators propose that such competition shifts the balance between filament assembly and disassembly, which in turn affects how readily a cell extends protrusions and migrates. Most of the supporting observations come from cultured cells and purified protein systems rather than from intact organisms.
Animal work has examined the peptide in models of cardiac injury, skin wounding, and corneal repair, with reported outcomes covering cell migration, inflammatory cell influx, and tissue remodeling. Several of those experiments used the full-length protein or longer fragments instead of the seven-residue sequence, which makes direct comparison between reports difficult. Results are generally described as tissue-dependent, and effect sizes vary considerably across laboratories. Independent replication is uneven, so the overall picture is incomplete rather than settled.
Purity and identity are separate measurements and are often confused. Reverse-phase high-performance liquid chromatography, usually with ultraviolet detection near 214 nanometres, reports the share of total peak area belonging to the target compound. Mass spectrometry by electrospray or matrix-assisted laser desorption then checks whether the observed mass matches the expected sequence. Neither measurement alone shows that a vial holds the intended peptide. Peptide content, meaning the fraction of vial mass that is genuine peptide rather than counter-ion, water or residual acid, is reported separately and is frequently lower than the stated purity figure.
The regulatory position is broadly consistent across major jurisdictions: no thymosin beta-4 fragment is an approved medicine, and laboratory material is commonly labelled as not intended for human consumption. Anti-doping rules in sport list thymosin beta-4 and its fragments among prohibited peptide hormones. Because these products travel through research-chemical channels rather than pharmaceutical supply chains, quality varies considerably between vendors. Independent testing of identity, purity and sterility is the only dependable check, and a certificate of analysis describes one batch rather than a supplier's whole catalogue.
TB-500 is a laboratory label applied to a short synthetic peptide that is widely described as a fragment of thymosin beta-4, an actin-binding protein present in most mammalian cells. Suppliers and review articles usually present TB-500 as the N-terminal region of that protein, but the exact sequence attached to the name is not consistent across sources. Some product descriptions list a seven-residue chain; others use the label loosely for the parent protein itself. Because of that variation, any technical discussion of TB-500 needs to state which sequence is meant.
Thymosin beta-4 contains 43 amino acids and has a reported molecular mass near 4963 Da. The short fragment most often associated with the TB-500 label, an acetylated chain beginning LKKTETQ, has a reported mass near 889 Da, so the two are easily separated in analytical work. Mass spectrometry and amino acid analysis can confirm which material is present in a given sample. Statements treating TB-500 and thymosin beta-4 as interchangeable are therefore imprecise, even though the two appear together in much of the same literature.
Interest in the compound comes largely from studies of the parent protein, which participates in actin sequestration, cell migration and tissue repair processes. Whether a short fragment reproduces those activities is a separate question that remains open in the published record. Many summaries describe mechanisms by analogy to thymosin beta-4 rather than from direct measurements on the fragment. Claims about activity should be treated as provisional unless a cited study specifies the exact peptide, its purity and the assay used.
=== 2012—2017: ZeniMax Media subsidiaries === Antonov also worked on Dishonored's DLC. Following this, Antonov became the visual design director for American company ZeniMax Media, meaning he worked on projects developed by ZeniMax's subsidiary developers—including Bethesda Game Studios, MachineGames, id Software, and Arkane—and made sure "the level of visual design and fiction" coming out of them was "the highest possible", Robert Purchese wrote. In 2012, a ZeniMax subsidiary named BattleCry Studios was founded in Austin, Texas, by developer Rich Vogel. Antonov worked on their planned debut release, a team-based multiplayer FPS titled BattleCry. In 2015, Bethesda Softworks, the planned publisher of BattleCry, revealed their "concerns" about the viability of the game releasing, and it was cancelled in 2017. Antonov was the additional art director of MachineGames' Wolfenstein: The New Order (2014); a visual designer of Dire Wolf Digital's The Elder Scrolls: Legends (2017); and a consultant on Bethesda Game Studios' Fallout 4 (2015), id Software's Doom (2016), and Arkane's Dishonored 2 (2016) and Prey (2017).
To reduce poverty, encourage economic growth, and reduce congestion in Metro Manila, the Duterte administration launched its comprehensive infrastructure program, Build, Build, Build, on April 18, 2017. The program, which forms part of the administration's socioeconomic policy, aimed to usher in the country's "Golden Age of Infrastructure" by increasing the share of spending on public infrastructure in the country's gross domestic product (GDP) from 5.4 percent in 2017 to 7.4 percent in 2022. The administration, in 2017, shifted its infrastructure funding policy from public-private partnerships (PPPs) of previous administrations to government revenues and official development assistance (ODA), particularly from Japan and China, but has since October 2019 engaged with the private sector for additional funding. The administration revised its list of Infrastructure Flagship Projects (IFPs) under the Build, Build, Build program from 75 to 100 in November 2019, then to 104, and finally, to 112 in 2020, expanding its scope to include health, information and communications technology, and water infrastructure projects to support the country's economic growth and recovery from the COVID-19 pandemic. Some major projects include the Subic-Clark Railway, the North–South Commuter Railway from New Clark City to Calamba, Laguna, the Metro Manila Subway, the expansion of Clark International Airport, the Mindanao Railway (Tagum-Davao-Digos Segment), and the Luzon Spine Expressway Network.
==== Federal level ==== On 6 August 2020, US President Donald Trump signed an order which would ban TikTok transactions in 45 days if it was not sold by ByteDance. On 14 August 2020, Trump issued another order giving ByteDance 90 days to sell or spin off its US TikTok business. In the order, Trump said that there is "credible evidence" that leads him to believe that ByteDance "might take action that threatens to impair the national security of the United States". In June 2021, US President Joe Biden signed an executive order revoking the Trump administration ban on TikTok, and instead ordered the Secretary of Commerce to investigate the app to determine if it poses a threat to US national security. On 27 December 2022, the Chief Administrative Officer of the United States House of Representatives banned TikTok from all devices managed by the House of Representatives. On 30 December 2022, President Joe Biden signed the No TikTok on Government Devices Act, prohibiting the use of the app on devices owned by the federal government, with some exceptions. On 13 March 2024, the United States House of Representatives passed H.R. 7521, which would ban TikTok entirely unless it was divested from its Chinese parent company, ByteDance. In April, the House of Representatives included a revised version of the bill in a foreign aid package, which was passed by the Senate on 23 April 2024, and signed into law by President Joe Biden the following day. The law was challenged in TikTok, Inc. v. Garland but was upheld as constitutional.
Sources: en.wikipedia.org
==== MRI imaging ==== Typical MRI contrast agents that contain gadolinium and manganese are quickly excreted from the body and carry risks of increased toxicity. Nanogels aim to circumvent these limitations by encapsulating these agents and increasing their relaxivity, or sensitivity. One study encapsulated gadolinium-III within a nanogel and observed a significant enhancement in relaxivity compared to a clinically available formulation of gadolinium-III. Another group developed pH-responsive nanogels containing both manganese oxide and superparamagnetic iron oxide nanoparticles that successfully imaged small tumors, where the pH was more acidic compared to the surrounding healthy tissues. Fluorine-containing nanogels can also be used as tracers for 19F MRI, because their aggregation and tissue binding has only minor effect on their 19F MRI signal. Furthermore, they can carry drugs and their physico-chemical properties of the polymers can be highly modulated.
Delta sleep-inducing peptide, as the name suggests, induces delta wave EEG activity. Alcohol reduces SWS delta wave activity, thereby restricting the release of growth hormone (GH) by the pituitary. The muramyl peptide, muramyl dipeptide (MDP, N-acetylmuramyl-L-alanyl-D-isoglutamine) has been shown to increase delta wave activity during slow wave sleep. The drug gabapentin, a drug used to control epileptic seizures, increases delta-wave activity and slow wave sleep in adults. While hypnotics like zolpidem increase slow wave sleep, they do not increase delta wave activity, and instead increase spindle activity during slow wave sleep. Gamma-hydroxy butyrate (GHB) increases delta slow-wave sleep as well as sleep-related growth hormone (GH). Administration of high-dose nitrous oxide is associated with transient, large amplitude slow-delta oscillations.
== Enzymatic browning == Polyphenol oxidase is an enzyme found throughout the plant and animal kingdoms, including most fruits and vegetables. PPO has importance to the food industry because it catalyzes enzymatic browning when tissue is damaged from bruising, compression or indentations, making the produce less marketable and causing economic loss. Enzymatic browning due to PPO can also lead to loss of nutritional content in fruits and vegetables, further lowering their value. Because the substrates of these PPO reactions are located in the vacuoles of plant cells damaged mainly by improper harvesting, PPO initiates the chain of browning reactions. Exposure to oxygen when sliced or pureed also leads to enzymatic browning by PPO in fruits and vegetables. Examples in which the browning reaction catalyzed by PPO may be desirable include avocados, prunes, sultana grapes, black tea, and green coffee beans.
Sources: en.wikipedia.org
== Taxonomy and distribution == Within the world of taxonomy, the stable 'Classical System' of Michaelsen (1900) and Stephenson (1930) was gradually eroded by the controversy over how to classify earthworms, such that Fender and McKey-Fender (1990) went so far as to say, "The family-level classification of the megascolecid earthworms is in chaos." Over the years, many scientists have developed their own classification systems for earthworms, which led to confusion, and these systems have been and still continue to be revised and updated. The classification system used here which was developed by Blakemore (2000), is a modern reversion to the Classical System that is historically proven and widely accepted. Categorization of a megadrile earthworm into one of its taxonomic families under suborders Lumbricina and Moniligastrida is based on such features as the makeup of the clitellum, the location and disposition of the sex features (pores, prostatic glands, etc.), number of gizzards, and body shape. Currently, over than 6,000 species of terrestrial earthworms are named, as provided in a species name database, but the number of synonyms is unknown. The families, with their known distributions or origins:
=== Legal status === The US Food and Drug Administration (FDA) granted the application for efgartigimod alfa fast track and orphan drug designations. The FDA granted the approval of Vyvgart to Argenx BV. In June 2022, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Vyvgart, intended for the treatment of anti‑acetylcholine receptor (AChR) antibody positive generalized myasthenia gravis. The applicant for this medicinal product is Argenx. Efgartigimod alfa was approved for medical use in the European Union in August 2022.
Since children commonly strongly dislike the taste of castor oil, some parents punished children with a dose of it. Physicians recommended against the practice because it may associate medicines with punishment and make children afraid of the doctor.
The substance is quickly absorbed from the gut, but only to about 20% of the applied dose. Highest blood plasma concentrations are reached after 1 to 2.5 hours. When in the bloodstream, it is almost completely (99.9%) bound to plasma proteins, but apparently to different binding sites than warfarin, digoxin and other drugs with high plasma protein affinity. It is mainly metabolised to the sulfate, which accounts for 67% of the circulating drug after a single dose, and a methylated derivative, which accounts for 21%. Minor metabolites are a reduced derivative (<10%) and a glucuronide. All of these metabolites are inactive except the reduced derivative. Opicapone is eliminated with a terminal half-life of 0.7 to 3.2 hours. It is mainly excreted via the faeces (67%), and in form of the glucuronide also via the kidney (13%). The sulfate has a much longer half-life of 94 to 122 hours. Opicapone sulfate is transported by SLCO1B1; the possibility that it blocks this transporter has not been excluded. Opicapone itself and the sulfate are also transported by a number of other proteins, but given the low concentrations of the free substances in the blood plasma, this is very unlikely to give rise to drug interactions. Opicapone is a weak inhibitor of the liver enzymes CYP1A2, CYP2B6, CYP2C8, and CYP2C9. The only CYP interaction found in studies that is somewhat likely to be relevant is that with repaglinide, which is metabolised by CYP2C8. The metabolism of warfarin, a CYP2C9 substrate, is not measurably affected.
Sources: en.wikipedia.org
TB-500 is a name used for a short synthetic peptide fragment taken from the actin-binding region of thymosin beta-4. Material sold under this label is usually a lyophilized powder supplied for laboratory research rather than a licensed medicine. The commonly cited sequence is LKKTETQ.
The parent protein contains forty-three amino acids, while the fragment carries only a short motif from one region. The fragment can interact with actin in vitro, but it does not include the rest of the protein structure. Whether the shorter molecule behaves the same way in living systems is not settled.
Published controlled human studies are scarce, and most activity reports come from cell culture or animal models. Reviews often describe the evidence base as limited and methodologically uneven. Open questions include the relationship between route, dose, and measured outcomes.
Not necessarily. TB-500 is a commercial label that suppliers apply to synthetic peptides described as thymosin beta-4 or a fragment of it. Published research most often studies the full-length protein, so statements about one do not automatically transfer to the other.